Insulin Resistance

← Back to Conditions

Category: Metabolic Health  |  Also addressed: HOMA-IR, Hyperinsulinemia, Impaired Insulin Sensitivity

What Is Insulin Resistance?

Insulin resistance is a metabolic condition in which the body's cells become less responsive to insulin, the hormone responsible for regulating blood sugar. As a result, the pancreas produces progressively more insulin to compensate, often long before blood sugar levels become abnormal. The result is a prolonged window of metabolic dysfunction that standard glucose testing consistently misses.

This means many patients can have entirely normal fasting glucose and HbA1c while already experiencing significant metabolic disruption. The hormone driving that disruption, insulin, is rarely measured in conventional care. At The Lamkin Clinic, it is one of the first things we check.

Why It Matters

Insulin resistance is one of the most consequential and most underdiagnosed metabolic conditions in medicine today. Because insulin receptors are present in virtually every tissue in the body, chronic hyperinsulinemia produces downstream effects that reach far beyond blood sugar regulation.

• Weight gain, especially abdominal: Insulin is the body's primary fat-storage hormone. Chronically elevated insulin suppresses fat burning and promotes fat deposition, preferentially in the visceral compartment where it further worsens metabolic signaling.
• Fatigue and impaired energy: When cells cannot effectively take up glucose despite elevated insulin, mitochondrial fuel delivery is compromised. The result is persistent fatigue that does not resolve with more sleep or caffeine.
• Hormone imbalance: In men, insulin resistance suppresses testosterone production and reduces SHBG. In women, it amplifies LH-driven androgen production from the ovaries, driving the androgen excess pattern central to PCOS. Hormone therapy frequently underperforms when underlying insulin resistance has not been addressed.
• Cardiovascular disease: Hyperinsulinemia drives elevated triglycerides, low HDL, small dense LDL particles, hypertension, and vascular inflammation, the full cardiovascular risk cluster that accompanies metabolic syndrome.
• Type 2 diabetes: Insulin resistance is the upstream condition that precedes type 2 diabetes by a decade or more. Addressing it before glucose rises is the difference between prevention and management.

It is often present for years, sometimes decades, before a conventional diagnosis is made. That window of missed opportunity is exactly what early functional medicine evaluation is designed to close.

Common Symptoms

Many patients with insulin resistance have no symptoms at all in the early phase. When symptoms do appear, they are frequently attributed to stress, aging, or lifestyle without connecting them to an underlying metabolic driver. The following symptom cluster, particularly when several are present together, should prompt metabolic evaluation.

Root Causes: A Functional Medicine Perspective

Insulin resistance does not have a single cause. It emerges from the convergence of multiple physiological stressors, and identifying which combination is active in a given patient is the foundation of effective treatment. Addressing only one driver while others remain active produces partial and unsustained results.

Metabolic

Excess refined carbohydrate intake is the most direct dietary driver. Chronic postprandial insulin spikes from high-glycemic meals desensitize insulin receptors through downregulation over time. Fructose, particularly from added sugars and sweetened beverages, bypasses normal glucose-sensing controls and is preferentially converted to fat in the liver, producing hepatic insulin resistance even in patients with a relatively moderate overall caloric intake. Caloric overload and the resulting visceral adiposity compound these effects by releasing free fatty acids and pro-inflammatory adipokines directly into the portal circulation.

Hormonal

Cortisol is the most potent physiological antagonist of insulin action. Chronic psychological stress, poor sleep, and HPA axis dysregulation produce sustained cortisol elevation that directly impairs cellular insulin receptor sensitivity and promotes hepatic glucose production. Low testosterone in men reduces skeletal muscle mass, the primary site of insulin-mediated glucose disposal, and increases visceral fat accumulation, worsening insulin signaling through a self-reinforcing cycle. Thyroid dysfunction, particularly impaired T4-to-T3 conversion, reduces basal metabolic rate and glucose utilization in peripheral tissues.

Inflammation

Chronic low-grade systemic inflammation impairs insulin signaling at the molecular level through serine phosphorylation of the insulin receptor substrate (IRS-1), which blocks the normal downstream signaling cascade. Elevated hs-CRP, IL-6, and TNF-alpha, whether driven by visceral adiposity, gut permeability, chronic infection, or environmental toxin exposure, all contribute to this inflammatory insulin resistance pattern. This is why anti-inflammatory interventions are mechanistically relevant to metabolic treatment, not simply general wellness recommendations.

Gut

The gut microbiome is a direct regulator of metabolic health. Dysbiosis with reduced short-chain fatty acid (SCFA)-producing bacteria impairs the GLP-1 signaling that normally supports insulin sensitivity. Lipopolysaccharide (LPS) from gram-negative bacteria that translocates through a permeable intestinal barrier activates systemic inflammatory pathways that impair insulin receptor signaling in muscle and fat tissue. Restoring gut health in insulin-resistant patients frequently produces metabolic improvement that diet alone cannot fully explain.

Conventional vs Functional Medicine Approach

The conventional approach to insulin resistance has a timing problem. It waits until the condition crosses a glucose threshold into prediabetes or type 2 diabetes before treating aggressively, despite a decade of metabolic damage occurring during the silent compensated phase that precedes the diagnostic threshold.

Domain	Conventional Medicine	Functional Medicine
Detection	Fasting glucose and HbA1c; intervenes at diagnostic thresholds	Fasting insulin, HOMA-IR, and triglyceride:HDL ratio; identifies compensatory hyperinsulinemia before glucose rises
Primary marker	Blood glucose	Fasting insulin and HOMA-IR
Root cause	Weight and lifestyle as general categories	Specific drivers identified: cortisol burden, gut dysbiosis, hormonal deficiencies, inflammatory load
Treatment goal	Glucose normalization	Full insulin sensitivity restoration: HOMA-IR below 1.0, fasting insulin below 5 uIU/mL
Monitoring	Annual HbA1c	Serial fasting insulin, HOMA-IR, triglyceride:HDL, adiponectin, hormone panel

Key Labs to Evaluate

Standard metabolic panels are designed to diagnose diabetes, not detect its precursor. Identifying insulin resistance requires a targeted panel that measures insulin directly and assesses its metabolic consequences across multiple systems.

Core Panel

Lipid and Cardiovascular

Inflammation and Hormones

How to Interpret These Labs Together

Individual values in isolation have limited sensitivity for insulin resistance. The diagnostic signal comes from recognizing patterns across multiple markers simultaneously.

Pattern	What It Means
Fasting insulin above 7, glucose normal, HOMA-IR above 1.5, TG:HDL above 2.0	Early compensated insulin resistance. The highest-value intervention window. Most patients at this stage are told their labs are normal.
Fasting insulin above 10, fasting glucose 95 to 99, SHBG low, triglycerides elevated	Progressive insulin resistance with waning beta cell compensation. Cardiovascular risk already measurably elevated.
HbA1c 5.7 to 6.4%, fasting insulin beginning to fall, hs-CRP elevated, ApoB elevated	Prediabetes with inflammatory and cardiovascular sequelae. Falling insulin here reflects failing compensation, not improving sensitivity.
Normal labs across the board but persistent fatigue, weight gain, and hormone therapy underperformance	Insulin resistance is still the most likely undiagnosed driver. Fasting insulin and HOMA-IR are the tests that will find it.

Common Patterns Seen in Patients

• "Normal labs" but persistent fatigue: Fasting glucose 91 mg/dL. HbA1c 5.3%. Standard labs completely unremarkable. Fasting insulin 15 uIU/mL. HOMA-IR 3.4. Triglyceride:HDL ratio 3.2. This patient has significant insulin resistance that conventional screening has missed entirely. Once identified and treated, the fatigue, brain fog, and weight plateau that have not responded to anything else frequently resolve within 8 to 12 weeks.
• Weight gain despite calorie restriction: A patient reducing calories and exercising who cannot lose weight despite genuine adherence. Chronically elevated insulin suppresses lipolysis (fat breakdown) even during a caloric deficit. Until insulin is lowered through carbohydrate quality reduction, meal timing, and insulin-sensitizing interventions, the metabolic arithmetic simply does not work in their favor regardless of how much they restrict.
• Hormone therapy that is not working: A man on testosterone therapy whose testosterone levels are optimal on labs but who continues to report fatigue, low libido, and poor body composition response. Or a woman on bioidentical hormone therapy who sees minimal symptomatic improvement despite appropriate hormone levels. Insulin resistance impairs hormone receptor sensitivity and creates a metabolic environment in which administered hormones cannot produce their expected clinical effect. Treating the insulin resistance frequently unlocks the response that therapy alone could not achieve.

Treatment and Optimization Strategy

Nutrition

Reducing glycemic load is the most direct dietary intervention. This means lowering total net carbohydrate to a range that measurably reduces postprandial insulin spikes, typically 75 to 150 grams per day depending on the individual, while eliminating refined fructose from added sugars and sweetened beverages. Prioritizing protein at 1.0 to 1.4 grams per kilogram of body weight supports muscle preservation, satiety, and the thermic effect that improves insulin sensitivity. Time-restricted eating within an 8 to 10 hour daily window reduces total daily insulin exposure and allows the fasting period to support cellular insulin receptor resensitization. The target is not a specific named diet but a nutritional pattern that produces a fasting insulin below 5 uIU/mL and a HOMA-IR below 1.0.

Lifestyle

Resistance training is the single most potent lifestyle intervention for improving skeletal muscle insulin sensitivity. Skeletal muscle accounts for approximately 80% of insulin-stimulated glucose disposal; increasing muscle mass creates a larger glucose sink that reduces the insulin load required after meals. Three to four sessions of progressive compound resistance exercise per week produces measurable HOMA-IR improvement within 4 to 6 weeks independent of weight loss. Sleep optimization is equally non-negotiable: a single night of four hours of sleep reduces insulin sensitivity by approximately 25% in healthy adults, and chronic restriction below seven hours produces a cumulative metabolic deficit that dietary and exercise interventions cannot fully overcome.

Targeted Supplements

What Most Doctors Miss

• Not ordering fasting insulin: This is the most significant diagnostic gap in conventional metabolic screening. A fasting glucose of 92 mg/dL is normal by every laboratory reference range. If the fasting insulin required to maintain that glucose is 16 uIU/mL, the HOMA-IR is 3.7 and insulin resistance is clinically significant. Ordering glucose without insulin provides half the picture and reliably misses the condition during its most reversible phase.
• Insulin resistance is frequently present even when standard labs are normal: Normal glucose, normal HbA1c, and a normal lipid panel do not rule out insulin resistance. The compensatory hyperinsulinemia that defines early insulin resistance is invisible to tests that measure its downstream effects rather than the hormone itself.
• The triglyceride:HDL ratio is not routinely interpreted: This calculation, available for free from any standard lipid panel, is one of the most sensitive surrogate markers for insulin resistance. A ratio above 2.0 should prompt fasting insulin measurement in any patient with metabolic symptoms.
• Hormone therapy underperformance is a metabolic signal: When a patient on optimally dosed hormone therapy fails to experience the expected clinical response, insulin resistance is the most common unaddressed metabolic explanation. It is rarely investigated in this context and almost always present.
• Cortisol and sleep are treated as lifestyle factors rather than metabolic drivers: A patient sleeping five hours per night under chronic occupational stress has a physiological cortisol burden that is more powerful than most dietary carbohydrate loads in terms of its effect on insulin receptor sensitivity. Prescribing berberine and a low-carbohydrate diet without addressing cortisol and sleep creates a ceiling on metabolic progress that neither nutrition nor supplementation can overcome.

When to Seek Medical Care

If you experience persistent fatigue, weight gain despite genuine dietary effort, brain fog, difficulty with body composition despite exercise, hormone therapy that is not producing expected results, or any of the symptoms described above, insulin resistance warrants direct evaluation. You do not need to wait for blood sugar to rise before investigating metabolic function. In fact, the most important time to investigate is precisely when standard labs appear normal.

At The Lamkin Clinic, evaluation includes fasting insulin, HOMA-IR, a complete lipid particle analysis, inflammatory markers, and a full hormone panel reviewed together as an integrated metabolic picture rather than as isolated values.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches Insulin Resistance

Related Conditions

Related Symptoms